Ipamorelin Research Overview
Overview
Ipamorelin is a synthetic growth hormone secretagogue that selectively activates the growth hormone secretagogue receptor (GHS-R1a), the primary receptor involved in ghrelin-mediated growth hormone signaling. Unlike earlier growth hormone secretagogues, Ipamorelin demonstrates greater receptor selectivity and is associated with comparatively limited effects on cortisol, prolactin, and adrenocorticotropic hormone (ACTH) under evaluated study conditions.
The Ipamorelin molecule is a pentapeptide composed of five amino acids with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Its unique structure confers selective agonist activity at the GHS-R1a receptor, which is predominantly expressed in the pituitary gland, hypothalamus, and other tissues involved in growth hormone regulation. The selectivity of Ipamorelin is attributed to its specific amino acid sequence, which interacts with key residues in the receptor binding pocket.
Laboratory and human clinical studies have examined Ipamorelin for its ability to stimulate endogenous growth hormone secretion. Pharmacodynamic investigations have reported dose-dependent increases in circulating growth hormone following administration, with corresponding elevations in insulin-like growth factor-1 (IGF-1) under specific study conditions. The magnitude and duration of growth hormone stimulation appear to be dose-dependent and influenced by the route of administration.
The selectivity profile of Ipamorelin distinguishes it from earlier secretagogues, which were associated with broader hormonal effects. Earlier compounds such as GHRP-2 and GHRP-6 were reported to stimulate cortisol, prolactin, and ACTH secretion in addition to growth hormone. The more selective profile of Ipamorelin has made it a subject of interest for research examining growth hormone physiology without confounding effects on other endocrine axes.
Ipamorelin has been investigated in combination with GHRH analogs such as CJC-1295 and Sermorelin, as the two pathways (GHS-R1a and GHRH receptor) activate distinct intracellular signaling cascades that may have additive or synergistic effects on growth hormone secretion. This combination approach is based on established endocrine physiology and has been examined in various research protocols.
Key Scientific Characteristics
Synthetic pentapeptide growth hormone secretagogue
Selectively activates the growth hormone secretagogue receptor (GHS-R1a)
Demonstrates greater receptor selectivity compared with earlier growth hormone secretagogues
Associated with limited effects on cortisol, prolactin, and ACTH under evaluated study conditions
Investigated in laboratory and human clinical studies of growth hormone physiology
Evaluated for its effects on endogenous growth hormone and IGF-1 secretion
Not approved by the U.S. Food and Drug Administration for therapeutic use
Research Notes
Ipamorelin has been investigated as a research tool for studying the regulation of growth hormone secretion through the GHS-R1a pathway. Its selectivity profile has been evaluated in comparison with other growth hormone secretagogues, with studies reporting differences in hormonal effects across classes of compounds.
Additional clinical research is needed to further characterize the pharmacology, safety profile, and physiological effects of Ipamorelin. Studies have examined its potential applications in growth hormone research, although the overall body of published clinical evidence remains limited compared with some other GHS compounds.